Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Orexo AB ( (SE:ORX) ) has shared an announcement.
Orexo AB will publish its Full Year Report 2025 on 5 February at 7:00 a.m. CET, with a particular emphasis on fourth‑quarter developments and the operational and financial implications of the divestment of its US Zubsolv business. Later that day at 2:00 p.m. CET, the company will host a teleconference and audiocast presentation led by CEO Nikolaj Sørensen and CFO Fredrik Järrsten, offering analysts, investors, and media an opportunity to receive detailed commentary on the results and ask questions, underscoring Orexo’s efforts to maintain transparency with stakeholders during a period of strategic portfolio transition.
The most recent analyst rating on (SE:ORX) stock is a Hold with a SEK31.00 price target. To see the full list of analyst forecasts on Orexo AB stock, see the SE:ORX Stock Forecast page.
More about Orexo AB
Orexo AB is a Swedish biotechnology company focused on treatments for severe diseases and life‑saving rescue medications, leveraging its proprietary AmorphOX drug delivery technology to enhance bioavailability and stability for both large and small molecules. With more than 30 years of experience and several globally approved drugs, the Uppsala‑based company is advancing a diversified clinical and pre‑clinical pipeline in collaboration with external partners, and its shares are listed on Nasdaq Stockholm with ADRs traded on the OTCQX market in the US.
Average Trading Volume: 84,624
Technical Sentiment Signal: Buy
Current Market Cap: SEK1.04B
See more data about ORX stock on TipRanks’ Stock Analysis page.